Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 148 of the 158 references it cites were found in a registry or an index; 58 of the 131 sources its claims cite were checked for support.

The p53 Pathway in Glioblastoma

Open access

Abstract

The tumor suppressor and transcription factor p53 plays critical roles in tumor prevention by orchestrating a wide variety of cellular responses, including damaged cell apoptosis, maintenance of genomic stability, inhibition of angiogenesis, and regulation of cell metabolism and tumor microenvironment. TP53 is one of the most commonly deregulated genes in cancer. The p53-ARF-MDM2 pathway is deregulated in 84% of glioblastoma (GBM) patients and 94% of GBM cell lines. Deregulated p53 pathway components have been implicated in GBM cell invasion, migration, proliferation, evasion of apoptosis, and cancer cell stemness. These pathway components are also regulated by various microRNAs and long non-coding RNAs. TP53 mutations in GBM are mostly point mutations that lead to a high expression of a gain of function (GOF) oncogenic variants of the p53 protein. These relatively understudied GOF p53 mutants promote GBM malignancy, possibly by acting as transcription factors on a set of genes other than those regulated by wild type p53. Their expression correlates with worse prognosis, highlighting their potential importance as markers and targets for GBM therapy. Understanding mutant p53 functions led to the development of novel approaches to restore p53 activity or promote mutant p53 degradation for future GBM therapies.

Overview

CoChat Summary

TL;DR

This review summarizes the p53 pathway in glioblastoma, emphasizing frequent deregulation of p53-ARF-MDM2 components and the understudied oncogenic gain-of-function (GOF) mutant p53. It discusses mechanisms of GOF mut-p53 and therapeutic strategies to restore wild-type p53 or degrade mutant p53.

Key findings

  • The p53-ARF-MDM2 pathway is deregulated in 237/281 (84%) of GBM in TCGA and up to 94.1% of GBM cell lines; individual components are deregulated at TP53 22%, ARF 61%, MDM2 10%, and MDM4 10%, while CDKN2A/ARF homozygous deletion occurs in ~60% of GBM.
  • TP53 mutations occur in ~28% of tumors, with subtype prevalence of 54% proneural, 32% mesenchymal, 21% neural, and 0% classical; most are missense DNA-binding domain mutations, and >25% occur in six hotspots (R273, R248, R175, G245, R282, R249), producing highly expressed GOF mut-p53.
  • GOF mut-p53 promotes proliferation, migration, invasion, chemotherapy resistance, altered metabolism, and stemness; it can exert dominant-negative effects on wt-p53 and interact with p63/p73 and other transcription factors. The review notes TP53 mutational status has not been correlated with survival in GBM despite high mutation frequency, while GOF mut-p53 remains understudied.
  • Therapeutic approaches include MDM2/p53 inhibitors (e.g., nutlin3a, RG7112, AMG232), mutant p53 reactivation (PRIMA-1/APR-246, CP-31398, PEITC, ReACp53), and HDAC inhibitors to degrade mut-p53 (e.g., SAHA, CUDC-907); most have not been tested in GBM patients.

Methods

  • Design: narrative review; no primary experimental data or systematic review methodology stated.
  • Data/sample: synthesizes published literature and genomic datasets including TCGA/cBioPortal, GBM cell lines, patient-derived xenografts, mouse models, and clinical trials.
  • Analysis: thematic synthesis of p53 pathway deregulation, GOF mut-p53 mechanisms, non-coding RNA regulation, and p53-targeted therapies.

Limitations

  • Stated: GOF mut-p53 is understudied in GBM; most GBM p53 studies failed to distinguish TP53 deletion from GOF mutations; common mouse models rely on wt-p53 knockout rather than representative GOF knock-in models; exact timing of TP53 mutation in primary GBM is not discerned; p53 pathway therapeutic exploitation has not been very successful to date.
  • Evident: as a narrative review, it does not report a systematic search strategy, inclusion criteria, or quantitative synthesis, and it draws on heterogeneous preclinical models and datasets.
  • Evident: some cited findings are inconsistent (e.g., TP53 expression in recurrent tumors has inconsistent results; TP53 mutational status not correlated with GBM survival despite high mutation frequency), which limits firm conclusions.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/cancers10090297

Cites

148 of 148 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 The p53 pathway is highly deregulated in GBM (adapted from cBioportal) [22,23]. The most common mutations of the p53 pathway are missense mutations in TP53, deletions of CDKN2A/ARF, and/or amplifications of MDM2 and MDM4. These mutations often lead to diminished tumor suppressor activity.
Figure 1 The p53 pathway is highly deregulated in GBM (adapted from cBioportal) [22,23]. The most common mutations of the p53 pathway are missense mutations in TP53, deletions of CDKN2A/ARF, and/or amplifications of MDM2 and MDM4. These mutations often lead to diminished tumor suppressor activity.CC BY · PubMed Central
Figure 2 The p53-ARF-MDM2/4 pathway (adapted from the p53 website) [24]. In response to hyperproliferative stress and/or DNA damage, pathway mediators, such as ARF, are activated. MDM2 and MDM4 mark p53 for degradation, and are subsequently degraded when upstream mediators are activated. This releases p53 from degradation, and leads to increased cell cycle arrest, apoptosis, DNA Repair, and cellular senescence.
Figure 2 The p53-ARF-MDM2/4 pathway (adapted from the p53 website) [24]. In response to hyperproliferative stress and/or DNA damage, pathway mediators, such as ARF, are activated. MDM2 and MDM4 mark p53 for degradation, and are subsequently degraded when upstream mediators are activated. This releases p53 from degradation, and leads to increased cell cycle arrest, apoptosis, DNA Repair, and cellular senescence.CC BY · PubMed Central
Figure 3 Most TP53 mutations are in the DNA binding domain. (A) The schematic view of the domains of p53 protein. The protein has 393 residues with numerous different domains including the N-terminus (red), proline rich domain (orange), DNA binding domain (purple), tetramerization domain (green) and negative regulatory domain/C-terminus (blue). The peaks represent the frequency of mutations in cancer with the DNA binding domain containing the six hot spot mutations. (B) Ribbon diagram of DNA-bound p53 (PBD ID 2AHI). The residues highlighted in yellow represent residues that are hot spot mutations as well as other residues of interest. Modified and reprinted with permission from Springer Nature: [Springer Nature] [Oncogene] [112].
Figure 3 Most TP53 mutations are in the DNA binding domain. (A) The schematic view of the domains of p53 protein. The protein has 393 residues with numerous different domains including the N-terminus (red), proline rich domain (orange), DNA binding domain (purple), tetramerization domain (green) and negative regulatory domain/C-terminus (blue). The peaks represent the frequency of mutations in cancer with the DNA binding domain containing the six hot spot mutations. (B) Ribbon diagram of DNA-bound p53 (PBD ID 2AHI). The residues highlighted in yellow represent residues that are hot spot mutations as well as other residues of interest. Modified and reprinted with permission from Springer Nature: [Springer Nature] [Oncogene] [112].CC BY · PubMed Central
Figure 4 Summary of select strategies for the therapeutic targeting of mutant p53 in GBM. Approaches include restoration of wild type p53 activity or degradation of mutant p53.
Figure 4 Summary of select strategies for the therapeutic targeting of mutant p53 in GBM. Approaches include restoration of wild type p53 activity or degradation of mutant p53.CC BY · PubMed Central

Verification

Claims the paper makes

44 Valid · 3 Not valid · 34 Not checked · 6 Own results and interpretations

44 more claims · 22 with their cited sources checked

Create a free account to see all 87 claims and to verify the 9 references still open.

See all claims — free account
  • It may state two separate claims as one. 34
  • Probably not a substantial claim. 4

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 158 references

Cited by

See all 440

Metadata

Authors
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., Grello, C., Oxford, M., Yuan, F., & Abounader, R.
Affiliations
  • University of Virginia (US)
  • University of Virginia Cancer Center (US)
Corresponding author
Abounader, Roger
Venue
Cancers
Publisher
MDPI AG
Published
2018-09-01
Volume
10
Issue
9
Pages
297
ISSN
2072-6694 (ISSN-L)
OpenAlex
W2890896123
Cited by
440
References
158
Citations by year
2026: 42 · 2025: 66 · 2024: 76 · 2023: 52 · 2022: 80 · 2021: 60 · 2020: 50 · 2019: 13
FWCI
3.21
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institutes of Health (U01 CA220841, R01 NS045209)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords
p53, glioblastoma, TP53 mutation, tumor suppressor, apoptosis evasion, genome stability, tumor microenvironment, cell migration and invasion, cancer stemness, microRNA, long non-coding RNA, prognosis, therapeutic target

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The p53 Pathway in Glioblastoma. https://app.cochat.ai/papers/10.3390/cancers10090297
The paper
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., Grello, C., Oxford, M., Yuan, F., & Abounader, R. (2018). The p53 Pathway in Glioblastoma. Cancers. https://doi.org/10.3390/cancers10090297

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.